Authors: Sheau-Chiann Chen, Derek Shyr, Assaf P. Oron and Yu-Shyr
Reference
Oron, A. P., & Hoff, P. D. (2013). Small-sample behavior of novel phase I cancer trial designs. Clinical Trials, 10(1), 63-80.
You can first download the sample toxrate.csv or toxrate.txt files and then try uploading them. Also, you can upload randomly generated dose-toxicity curves generated by "Scenario Randomizer" (SCrandom.csv)
Reference
Babb, J., Rogatko, A. & Zacks, S. (1998). Cancer phase I clinical trials: Efficient dose escalation with overdose control. Statistics in Medicine, 17(13), 1103-1120.
Bolognese, J. (2016). Consideration of the T-Statistic adaptive dose-finding design for estimating maximum tolerated dose. 2016 Joint of Statistical Meetings, McCormick Place Convention Center, Chicago, USA. https://ww2.amstat.org/meetings/jsm/2016/onlineprogram/AbstractDetails.cfm?abstractid=318637
Cheung, Y. K. (2011). Dose finding by the continual reassessment method: CRC Press.
Cheung, K. (2013). dfcrm: Dose-finding by the continual reassessment method. R package version 0.2-2. https://CRAN.R-project.org/package=dfcrm
Durham, S., & Flournoy, N. (1994). Random Walks for Quantile Estimation. In S. Gupta & J. Berger (Eds.), Statistical Decision Theory and Related Topics V (pp. 467-476): Springer New York.
Gezmu, M. (1996). The geometric up-and-down design for allocating dosage levels. (PhD degree), American University.
Ivanova A., Bolognese, J., & Perevozskaya I. (2008). Adaptive dose finding based on t-statistic for dose-response trials. Statistics in Medicine, 27(10), 1581-1592.
Ji, Y., Li, Y., & Bekele, B. N. (2007). Dose-finding in phase I clinical trials based on toxicity probability intervals. Clinical Trials, 4(3), 235-244.
Ji, Y., Liu, P., Li, Y., & Bekele, B. N. (2010). A modified toxicity probability interval method for dose-finding trials. Clinical Trials, 7(6), 653-663.
Ji, Y., & Wang, S.-J. (2013). Modified toxicity probability interval design: a safer and more reliable method than the 3+ 3 design for practical phase I trials. Journal of Clinical Oncology, 31(14), 1785-1791.
Liu, S., & Yuan, Y. (2015). Bayesian optimal interval designs for phase I clinical trials. Journal of the Royal Statistical Society: Series C (Applied Statistics), 64(3), 507-523.
Neuenschwander, B., Branson, M., & Gsponer T. (2008). Critical aspects of the Bayesian approach to phase I cancer trials. Statistics in Medicine, 27(13), 2420-2439.
O'Quigley, J., Pepe, M., & Fisher, L. (1990). Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer. Biometrics, 46(1), 33-48.
Simon, R., Freidlin, B., Rubinstein, L., Arbuck, S. G., Collins, J., & Christian, M. C. (1997). Accelerated titration designs for phase I clinical trials in oncology. Journal of the National Cancer Institute, 89(15), 1138-1147.
Storer, B. E. (1989). Design and analysis of phase I clinical trials. Biometrics, 45(3), 925-937.
Sweeting, M., Mander, A., & Sabin, T. (2013). bcrm: Bayesian Continual Reassessment Method Designs for Phase I Dose-Finding Trials. Journal of Statistical Software, 54(13), 1-26.
Wetherill, G. B. (1963). Sequential Estimation of Quantal Response Curves. Journal of the Royal Statistical Society. Series B (Methodological), 25(1), 1-48.